Literature DB >> 23147791

Chronic lymphocytic leukemia: a tale of one or two signals?

Nicholas Chiorazzi1, Dimitar G Efremov.   

Abstract

The significant correlation between disease aggressiveness and the gene and protein structures of the B-cell receptors (BCRs) expressed on chronic lymphocytic leukemia (CLL) cells, together with the evidence for chronic activation of the BCR pathway, have led to the hypothesis that this leukemia initiates and progresses by selecting normal B lymphocytes reactive with a restricted set of (auto)antigens. A study recently published in Nature identified a novel signal-initiating interaction between the third complementary determining region of the IG heavy chain variable domain (HCDR3) and an epitope in the second framework region (FR2) that appears to be unique to CLL B cells and that calls into question the need for classical antigen binding in the activation and expansion of the leukemic cells. These findings are discussed in the context of available information about the antigen reactivity of CLL B cells and its potential role in clonal survival and drive.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147791      PMCID: PMC3567819          DOI: 10.1038/cr.2012.152

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  16 in total

1.  A VH11V kappa 9 B cell antigen receptor drives generation of CD5+ B cells both in vivo and in vitro.

Authors:  M J Chumley; J M Dal Porto; S Kawaguchi; J C Cambier; D Nemazee; R R Hardy
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

Review 2.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

3.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

Authors:  Anna Lanemo Myhrinder; Eva Hellqvist; Ekaterina Sidorova; Anita Söderberg; Helen Baxendale; Charlotte Dahle; Kerstin Willander; Gerard Tobin; Eva Bäckman; Ola Söderberg; Richard Rosenquist; Sohvi Hörkkö; Anders Rosén
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

4.  B-cell clones as early markers for chronic lymphocytic leukemia.

Authors:  Ola Landgren; Maher Albitar; Wanlong Ma; Fatima Abbasi; Richard B Hayes; Paolo Ghia; Gerald E Marti; Neil E Caporaso
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

5.  Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation.

Authors:  Rosa Catera; Gregg J Silverman; Katerina Hatzi; Till Seiler; Sebastien Didier; Lu Zhang; Maxime Hervé; Eric Meffre; David G Oscier; Helen Vlassara; R Hal Scofield; Yifang Chen; Steven L Allen; Jonathan Kolitz; Kanti R Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2008-09-25       Impact factor: 6.354

6.  Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Authors:  Aleksandar Petlickovski; Luca Laurenti; Xiaoping Li; Sara Marietti; Patrizia Chiusolo; Simona Sica; Giuseppe Leone; Dimitar G Efremov
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

7.  Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity.

Authors:  Maxime Hervé; Kai Xu; Yen-Shing Ng; Hedda Wardemann; Emilia Albesiano; Bradley T Messmer; Nicholas Chiorazzi; Eric Meffre
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

8.  Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.

Authors:  Marta Muzio; Benedetta Apollonio; Cristina Scielzo; Michela Frenquelli; Irene Vandoni; Vassiliki Boussiotis; Federico Caligaris-Cappio; Paolo Ghia
Journal:  Blood       Date:  2008-02-21       Impact factor: 22.113

9.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.

Authors:  Marcus Dühren-von Minden; Rudolf Übelhart; Dunja Schneider; Thomas Wossning; Martina P Bach; Maike Buchner; Daniel Hofmann; Elena Surova; Marie Follo; Fabian Köhler; Hedda Wardemann; Katja Zirlik; Hendrik Veelken; Hassan Jumaa
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

10.  Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.

Authors:  S Gobessi; L Laurenti; P G Longo; L Carsetti; V Berno; S Sica; G Leone; D G Efremov
Journal:  Leukemia       Date:  2008-12-18       Impact factor: 11.528

View more
  16 in total

Review 1.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

2.  Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones.

Authors:  Karla Plevova; Hana Skuhrova Francova; Katerina Burckova; Yvona Brychtova; Michael Doubek; Sarka Pavlova; Jitka Malcikova; Jiri Mayer; Boris Tichy; Sarka Pospisilova
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

3.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

4.  Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Authors:  Stephanie A Planque; Yukie Mitsuda; Vida Chitsazzadeh; Santhi Gorantla; Larisa Poluektova; Yasuhiro Nishiyama; Christina Ochsenbauer; Mary-Kate Morris; Gopal Sapparapu; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

Review 5.  Targeted therapy for chronic lymphocytic leukemia: current status and future directions.

Authors:  Jon E Arnason; Jennifer R Brown
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

6.  Signal-dependent and signal-independent functions of the B-cell receptor in chronic lymphocytic leukemia.

Authors:  Dimitar G Efremov; Stefania Gobessi
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

Review 7.  Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.

Authors:  Jon E Arnason; Jennifer R Brown
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

Review 8.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

9.  The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.

Authors:  Mariela Sivina; Robert J Kreitman; Evgeny Arons; Farhad Ravandi; Jan A Burger
Journal:  Br J Haematol       Date:  2014-04-02       Impact factor: 6.998

10.  Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.

Authors:  Stefano Iacovelli; Eva Hug; Sara Bennardo; Marcus Duehren-von Minden; Stefania Gobessi; Andrea Rinaldi; Mirza Suljagic; Daniel Bilbao; Giulia Bolasco; Julia Eckl-Dorna; Verena Niederberger; Francesco Autore; Simona Sica; Luca Laurenti; Hongsheng Wang; Richard J Cornall; Stephen H Clarke; Carlo M Croce; Francesco Bertoni; Hassan Jumaa; Dimitar G Efremov
Journal:  Blood       Date:  2015-01-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.